BRIEF-GSK, Theravance say positive FF/VI phase III study to support filing in Japan By: Reuters: Company News April 22, 2014 at 08:42 AM EDT * GSK & Theravance announce phase III study of FF/VI in COPD commenced to support potential future filing in Japan Read More >> Related Stocks: Gsk Plc ADR